Table 2.
Multivariate cox regression analyses for the prognosis of predicted risk groups after adjustment for other clinical variables in case of distant recurrence (DR, p = 0.005) and overall survival (OS, p = 0.01), respectively.
| Groups | DR | OS | ||
|---|---|---|---|---|
| HR [95% CI] | P-value | HR [95% CI] | P-value | |
| Risk | ||||
| Low-risk | 1 (Reference) | - | 1 (Reference) | - |
| High-risk | 6.76 [1.8;25.42] | 0.005 | 6.06 [1.55;23.74] | 0.01 |
| Age (years) | ||||
| >50 | 1 (Reference) | - | 1 (Reference) | - |
| ≤ 50 | 0.86 [0.51;1.44] | 0.563 | 0.68 [0.38;1.19] | 0.175 |
| LN | ||||
| Positive | 1 (Reference) | - | 1 (Reference) | - |
| Negative | 1.64 [0.88;3.05] | 0.116 | 1.6 [0.79;3.22] | 0.189 |
| Stage | ||||
| I | 1 (Reference) | - | 1 (Reference) | - |
| II | 1.35 [0.76;2.4] | 0.3 | 1.45 [0.76;2.77] | 0.264 |
| III | 2.08 [0.59;7.3] | 0.253 | 1.59 [0.34;7.46] | 0.557 |
| Grade | ||||
| 1 | 1 (Reference) | - | 1 (Reference) | - |
| 2 | 2.14 [0.77;5.97] | 0.146 | 1.81 [0.63;5.25] | 0.272 |
| 3 | 1.2 [0.4;3.62] | 0.748 | 1.21 [0.38;3.86] | 0.752 |
| PAM50 | ||||
| Luminal A | 1 (Reference) | - | 1 (Reference) | - |
| Normal-like | 0.6 [0.13;2.64] | 0.496 | 0.7 [0.16;3.16] | 0.645 |
| Luminal B | 1.58 [0.84;2.98] | 0.159 | 1.29 [0.65;2.59] | 0.469 |
| HER2-enriched | 0.81 [0.25;2.68] | 0.731 | 1.01 [0.29;3.47] | 0.986 |
| RT | ||||
| No | 1 (Reference) | - | 1 (Reference) | - |
| Yes | 0.88 [0.47;1.66] | 0.701 | 0.71 [0.36;1.41] | 0.326 |
| CT | ||||
| No | 1 (Reference) | - | 1 (Reference) | - |
| Yes | 0.36 [0.11;1.12] | 0.077 | 0.3 [0.09;1] | 0.05 |
| Interaction: CT Vs. risk | 0.36 [0.09;1.51] | 0.163 | 0.36 [0.08;1.68] | 0.195 |
The results show that there is no association between chemotherapy and risk groups (DR: p = 0.163; OS: p = 0.195).
DR, distant recurrence; OS, overall survival; CT, chemotherapy; RT, radiotherapy.